Jeff Bezos Backed Grail Before It Lost Half Its Value. Here's Whether He Was Early -- or Just Wrong.

Grail's stock crashed 50% in February after its NHS-Galleri multi-cancer early detection test failed to meet its primary endpoint of reducing late-stage cancer detection. However, the stock has partially recovered on optimism about favorable results in 12 specific cancer types. The company's future depends on FDA approval and insurer adoption, which will hinge on cost-benefit analyses by medical insurers.